

# Prediction of 10yr distant recurrence (DR) using the Prosigna<sup>®</sup> (PAM50) assay in histological subgroups of a DBCG cohort of postmenopausal Danish women with hormone receptor-positive (HR+) early breast cancer (EBC) allocated to 5yr of endocrine therapy (ET) alone

Anne-Vibeke Lænkholm<sup>1</sup>, Maj-Britt Jensen<sup>2</sup>, Jens Ole Eriksen<sup>1</sup>, Torben Kibøl<sup>1</sup>, Birgitte Bruun Rasmussen<sup>3</sup>, Ann S. Knoop<sup>4</sup>, Wesley Buckingham<sup>5</sup>, Sean Ferree<sup>5</sup>, Taryn Haffner<sup>5</sup>, Carl Schaper<sup>5</sup>, Bent Ejler Jensen<sup>2,4</sup>

1. Department of Pathology, Region Zealand
  2. The Danish Breast Cancer Cooperative Group, DBCG Secretariat, Rigshospitalet
  3. Department of Pathology, Herlev Hospital
  4. Department of Oncology, Rigshospitalet
  5. NanoString Technologies, Inc., Seattle, WA
-